Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOES: Depigoid DUO Grass-Mix/Olea versus placebo for allergic rhinoconjunctivitis with or without asthma
2025-521709-42-00Phase 3Authorised
- Sponsor
- LETI Pharma
- Start
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) and asthma comparing Depigoid DUO Grass-Mix/Olea with Placebo (2 arms). Primary endpoint: Mean combined symptom and medication score at peak pollen season. Planned start Jun 2026; status: authorised.
02
Drugs
depigoid + grasses pollen + olea europaea pollen
03
Conditions
allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2025-521709-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521709-42-00.